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Background: Erythropoietin (rHuEPO) therapy improves the success of autologous blood 
(AB) donation programs before elective surgery. We aimed at evaluating iron absorption 
during an AB donation program with or without rHuEPO. 
Study design and methods: 32 patients were randomized between placebo (group 1), 300 
(group 2) or 600 UI/kg rHuEPO (group 3) on 1st, 2nd and 3rd donation visits. All patients 
also received daily oral iron (200 mg Fe+). 
Results: The number of units collected in group 3 was higher than in group 1 (4.6 ± 0.5 vs 3.6 
± 0.8 units, p<0.01). RBC production increased in a rHuEPO dose-dependent manner. With 
rHuEPO, the RBC volume collected/unit presented a lower decrease with number of donated 
units than with placebo and was similar to that of homologous blood units. Storage iron did 
not influence the number of units collected, whereas circulating mobilizable iron was the 
limiting factor. Oral iron absorption increased in a rHuEPO dose-dependent manner (12-fold 
with 600 UI/kg rHuEPO) and was proportional to erythropoietic activity. 
Conclusion: rHuEPO does not only improve the number of AB units collected but also their 
quality. Storage iron cannot meet marrow iron requirements, but rHuEPO strongly increased 
oral iron absorption in a dose-dependent fashion through stimulation of erythropoietic 
activity.
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Orthopedic and cardiac surgery often lead to substantial blood loss and thus require red cell 
transfusions. Allogeneic blood transfusions carry some risk for complications, such as 
transmission of viral infections, transfusion reactions, alloimmunisation and immune 
suppression.1 Inclusion of patients who are planned for elective surgery in autologous blood 
(AB) donation programs represents an alternative to allogeneic blood transfusions.2-3 One unit 
of AB can be donated every 72 hours provided that the hematocrit (Hct) remains higher than 
33%. The main limitations to the predonation of the required amount of blood are iron-
restricted erythropoiesis4-5 and an unadapted endogenous erythropoietin (EPO) response to 
serial phlebotomy.6 While basal red blood cell (RBC) production in response to phlebotomy-
induced anemia is doubled,7 iron availability becomes the limiting factor for efficient 
erythropoiesis. Conversely, such iron-restricted erythropoiesis is not encountered in patients 
with genetic hemochromatosis (7-fold basal RBC production)8 or in patients receiving 
intravenous iron supplementation (3.5 to 4.5 fold basal RBC production).9 Previous studies 
have shown that storage, circulating and total body iron were lower in patients unable to 
donate the required amount of blood even with an oral iron supplementation of 375 mg iron 
sulfate three times a day.7 These data suggest that oral iron absorption could be insufficient to 
meet the demand created by increased erythropoietic activity. However, a randomized 
controlled study comparing the efficacy of oral (100 mg Fe+ TID) and intravenous (200 mg 
Fe+) iron supplementation did not show any improvement of the success of AB donation with 
either of the applied regimens.10 
The relationship between the degree of anemia and log(endogenous EPO levels) is known to 
be linear.11 However, for hemoglobin (Hb) levels above 10.5 g/dL, endogenous EPO levels do 
not increase above the normal range and the correlation between Hb and EPO levels does not 
remain true.12 This may lead to uncompensated anemia in response to serial phlebotomy.13 As 
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a consequence, the red cell content of each AB unit collected is 20% lower than in allogeneic 
blood units.13 
The use of recombinant human erythropoietin (rHuEPO) in AB donation programs results 
from these observations. A meta-analysis examining the effect of rHuEPO therapy on the 
capacity of patients to donate autologous blood before elective surgery concluded that the 
odds ratio for the proportion of patients transfused with allogeneic blood was 0.42 (CI 0.28-
0.62) for orthopedic surgery and 0.25 (CI 0.08-0.82) for cardiac surgery.14 Goodnough et al.15,
in a prospective, randomized, double-blind study, have shown that patients treated with 600 
U/kg rHuEPO TIW for 21 days of AB donation (6 units  collected) were able to procure more 
units and a higher RBC volume than patients receiving placebo. The hematocrit values and 
the reticulocyte response were also significantly higher in the rHuEPO group by the third 
visit. Nevertheless, the success of AB collection remained dependent on the initial 
mobilizable circulating iron. However, whereas the role of rHuEPO is to increase mobilizable 
circulating iron,15 the source of this iron, either storage iron or orally absorbed iron, has not 
been demonstrated.  
The current study was performed to examine how oral iron supplementation was useful to 
support erythropoiesis when stimulated by rHuEPO during an AB donation program. We 
aimed at identifying the source of iron used for RBC production under rHuEPO stimulation 
and at estimating the total amount of excess iron absorbed during that period. 
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Thirty-two patients scheduled for elective orthopedic (23 total hip arthroplasties and 8 total 
knee arthroplasties) or cardio-vascular surgery (I aortic valve replacement) were included. 
They were randomly assigned to three groups. Group 1 was treated with placebo (N = 10). In 
group 2, patients were treated with 300 UI/kg rHuEPO on1st, 2nd and 3rd donation visits (days 
0, 4 and 7) (N = 11). Patients in group 3 received a rHuEPO dose of 600 UI/kg at the same 
interval than group 2 (N = 11). The patients included in this study were part of a cohort of 
patients included in a milticentric trial to evaluate the safety and efficacy of epoietin alpha in 
autologous blood donation program. This study is a sub-analysis concerning iron metabolism 
in this field. All the patients from our center included in the multicentric study were included 
in the present study. The characteristics of the population are shown in table 1. 
Randomization resulted in patients similar for age, sex, baseline Hb or Hct level and baseline 
iron status. All patients signed an informed consent form before inclusion into the study and 
the protocol was approved by the Ethics Committee of the University of Liège. 
 
Study design
Visits were scheduled on days 0, 4, 7, 11 and 14. At each visit, one unit (450 mL) of AB was 
collected as long as Hct remained > 33%, with a maximum of 5 AB units. Placebo or rHuEPO 
was administered subcutaneously, on days 0, 4, 7. All patients received 200 mg Fe+ as oral 
ferrous sulfate and 5 mg folate, orally, from day 0 to discharge. Surgery was scheduled on day 
21. Blood samples were drawn at each visit, on the evening of the day of surgery, on post-
operative day +3 and on the day of discharge. 
 
Laboratory tests
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All blood cell parameters were determined using the Technicon H3 cell counter (Bayer, 
Tarrytown, NY, USA). Serum ferritin was measured by enzyme-linked immunoadsorbent 
assays. Serum soluble transferrin receptors were measured by an enzyme-linked 
immunosorbent assay (Quantikine™ IVD™, R&D Systems, Minneapolis, USA). Serum EPO 
was evaluated by radioimmunoassay (Diasorin, Stillwater, MN, USA) 
Formulas
Blood volume (BV; mL) = body weight (kg) x 60 (mL/kg). 
Red cell mass (RCM; mL) = BV x (Hct x 0.92)/100. 
Red blood cell volume donated (Don RBC; mL) = blood volume donated (mL) x same day 
Hct (%). 
RBC production (RBC prod; mL) = (RCM 2 – RCM 1) + Don RBC 
Donated Hb (gr) = blood volume donated (mL) x Hb (gr/dL)/100. 
Donated iron (Don I; mg) =  (Donated Hb x 3.4). 
Storage iron (SI; mg) = 400 + (ln ferritin – ln 12).16 
Mobilizable circulating iron (MCI; mg) = BV x ((Hct-34)/100).15,17 
Total mobilizable iron (TMI; mg) = SI + MCI. 
RBC iron (RBC I; mg) = (BV x Hb (g/dL) x 3.4 x 0.92)/100. 
Total iron (TI; mg): SI + RBC I + Don I. 
Absorbed iron (Abs I; mg) = TI pre-surgery – TI baseline. 
 
Statistical analyses
Values in text are expressed as mean ± standard deviation (M ± SD). Values in graphs are 
shown as mean ± standard error the mean (M ± SEM). Comparisons between groups have 
been performed using Student’s t tests for unpaired data. Linear correlations were performed 
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using Spearman’s correlation coeficients. All statistical analyses were performed with 
GraphPad Prism 4 (GraphPad, San Diego, CA, USA). 
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Blood donation (Table 2) 
 
There was a dose-response difference in the number of units that was collected etween 
groups. The target of 5 units/patient was achieved in 91% of patients in group 3 vs 82% in 
group 2 and 72% in group 1. The number of units collected in groups 1, 2 and 3 were 3.6 ± 
0.8, 4.1 ± 0.5 and 4.6 ± 0.5 per patient, respectively.  Compared to group 1, the difference was 
significant (p < 0.01) with group 3 receiving 600 UI/kg rHuEPO, and was at the limit of 
significance (p = 0.058) with group 2. RBC volume/unit donated was better in group 3 
compared to groups 2 (NS) and 1 (p < 0.05) (Figure 1). Hence, the total RBC volume donated 
in group 3 was about 50% higher than in group 1 (Table 2). 
 
Erythropoiesis
At baseline, the endogenous EPO level of group 3 was significantly higher compared to the 
placebo group but within the normal range. The reticulocyte count, at baseline, was higher in 
group 2 when compared with the 2 other groups but within the normal range.  
Cumulative RBC production was significantly increased by rHuEPO therapy in a dose-
dependent manner (Figure 2). The difference became significant by visit 3 (day 7). Total Hb 
production was also significantly different (group 1: 105.1 ± 44.5 gr, group 2: 151.7 ± 41.1 gr, 
group 3: 191.5 ± 44.4 gr Hb; p = 0.02 (group 2 vs group 1), p < 0.001 (group 3 vs group 1), p 
= 0.009 (group 3 vs group 2)). As shown by soluble transferrin receptors (sTfR) levels, 
erythropoietic activity remained stable throughout the study in group 1 but was strongly 
stimulated in patients receiving rHuEPO (74% increase in group 2 and 117% increase in 
group 3) (Figure 3). After cessation of rHuEPO therapy, erythropoietic activity progressively 
returned to baseline before surgery when it was quite similar in the 3 groups. Reticulocytes 
peaked at visit 4 in patients receiving rHuEPO (p < 0.001 for group 2 and 3 vs group 1). 
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Serum EPO peaked at visit 3 in group 3, 4 days earlier than the peak of reticulocytes and was 
significantly higher than in group 1 (p = 0.005) or group 2 (p = 0.048). 
Despite higher amounts of blood donated under rHuEPO therapy, and because of differences 
in RBC and Hb production, Hb (group 1: 11.5 ± 0.8; group 2: 12.0 ± 0.9; group 3: 11.9 ± 1.0 
g/dL; NS) and Hct values before surgery remained similar in the three groups (Figure 3). 
 
Blood losses and transfusions
Blood losses during surgery were similar among the 3 groups (group 1: 1,784 ± 902; group 2: 
1,427 ± 921; group 3: 1,414 ± 595 mL; NS). All patients required transfusions during or after 
surgery. There were no difference in the total number of units transfused (group 1: 4.0 ± 1.6; 
group 2: 3.5 ± 0.8; group 3: 3.8 ± 1.6; NS) . However, because of differences in the number of 
units collected, allogeneic transfusions were necessary for 1 patient in group 3 (5% of 
rHuEPO-treated patients) and 4 in group 1 (40% of the placebo group) (p = 0.01).  
 
Iron metabolism
Data concerning iron metabolism are summarized in table 3. Ferritin, serum iron and 
transferin saturation decreased significantly during the donation period. As a consequence, 
calculated storage iron (SI) decreased. Mobilizable circulati g iron (MCI) also decreased 
following phlebotomies, whereas total iron (TI) increased from baseline to pre-surgery since 
it integrates both body iron (storage iron and RBC iron) and donated iron. 
The difference between TI before surgery and TI at baseline represents an estimate of excess 
iron absorption during this period. As shown in table 3, iron absorption was rHuEPO dose-
dependent with little additional iron absorbed in the placebo group (47 ± 198 mg) but large 
amounts of orally absorbed iron in groups 2 (325 ± 341 mg) and 3 (593 ± 286 mg). Iron 
absorption correlated with the reticulocyte peak on day 11 (r = 0.41; p < 0.05) (figure 4),  with 
baseline TSAT (r = 0.35; p = 0.08) and with the sTfR peak on day 11 (r = 0.33; p = 0.09) but 
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neither with the EPO peak on day 7 (r = 0.19; NS), nor with baseline ferritin (r = 0.16; NS), 
baseline SeFe (r = 0.30; ), baseline  or presurgery sTfR/log(ferritin) (r = -0.06 and r = -0.07 
respectively; NS). The number of units collected correlated with MCI (r = 0.60; p< 0.01) 
(figure 5)  and in a lower measure with baseline Hct (r = 0.35; p < 0.05) but neither with SI 
nor TI. 
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Whereas blood transfusions are often needed with invasive surgical procedures and cannot be 
avoided, the use of AB donations allows to reduce the use of allogeneic transfusions. Thereby 
some of the risks of such transfusions, such as transmission of infectious diseases and 
immunization, can be limited. RHuEPO treatment improves AB collection through an 
increase in the number of units than can be donated.15,18-19 RHuEPO therapy further increases 
RBC production. A previous study showed that it leads to RBC production equivalent to 5 
units of blood during the donation period, whereas a placebo group produced only 3 units.20 
This stimulation of erythropoiesis also allows the red cell mass to return to normal before 
surgery in patients treated with rHuEPO.21 
In addition to confirming the success rate of AB donation with rHuEPO, our study has shown 
that, through faster and larger increase in RBC production, the RBC volume of a single unit 
remained far more stable throughout successive phlebotomies with rHuEPO compared to 
placebo. Therefore, the RBC volume in AB units collected remained nearly equivalent to that 
of allogeneic donations in the group treated with 600 UI/kg rHuEPO. Hence, not only the 
quantity but also the quality of AB donations was improved. 
The best predictor of the number of units collected was, in our study, the mobilizable 
circulating iron. Goodnough et al.15 have also showed a significant correlation between MCI 
and the number of units collected. However, in their study, baseline Hct was the strongest 
predictor of the number of units collected. This was not the case in our study. In this study, 
the strongest predictor was MCI. This observation was true for the rHuEPO-treated groups as 
well as for the placebo group. This means that, in case of intensive phlebotomies, whether 
erythropoiesis is stimulated or not by exogenous erythropoietin, mobilisation of storage iron 
may be too slow or inefficient for the requirements of RBC production. The implication of 
this observation is that there is a need for another source of iron through oral or intravenous 
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supplementation. Many studies in chronic renal failure have demonstrated the importance of 
iron supplementation in the long-term treatment of renal anemia by rHuEPO.22-23 Moreover, 
in our study, patients unable to donate more than 3 units during the donation period were 
those with the lowest basal MCI, TI and SI. This would suggest that early iron 
supplementation would be possibly helpful during rHuEPO therapy in iron-deficient patients. 
Despite the indirect proof of exogenous iron requirement during stimulation of erythropoiesis, 
the utility of iron suplementation for AB donation stimulated by rHuEPO remains 
controversial.4, 10, 24-26 Through calculated evaluation of iron pools in the different 
compartments of the body and donated blood units, we were able to estimate the total amount 
of orally absorbed iron throughout the pre-surgery period. Despite some consumption of 
storage iron, as shown by a decrease of ferritin levels during the pre-surgery period, 
stimulated erythropoiesis depended largely on an external iron supply. SI estimation from 
serum ferritin levels may be a little underestimated during rHuEPO therapy because erythroid 
marrow expansion drives down the labile iron pool in macrophages and thereby decreases 
serum ferritin even when iron stores remain constant.6 However, this was no longer the case 
at time of surgery because erythropoietic activity had virtually returned to normal. We found 
greatly increased iron absorption in the rHuEPO groups when compared to the placebo group. 
With reference to an iron absorption of 1 mg/d in iron-replete normal individuals, iron 
absorption was more than doubled (2.2 mg/d) in the placebo group. In group 2, iron 
absorption was increased 15.5-fold compared to normal individuals and 7-fold compared to 
group 1, whereas in group 3 it increased 28.2-fold and 12.8-fold, respectively. Iron absorption 
was, thus, EPO dose-dependent. Our results show that increased erythropoietic activity, and 
not EPO levels per se, was responsible for enhanced iron absorption. Using a technique of 
radioiron absorption and incorporation into red cells, Skikne et al.27 have demonstrated 
increased oral absorption of non-heme iron (3.5-9 fold) following administration fo rHuEPO 
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to normal subjects. We demonstrated that this holds true with even stronger stimulation of 
erythropoiesis over a longer period of time. Thus, our study suggests that erythropoietic 
stimulation by rHuEPO could even be a much stronger stimulator of iron absorption than 
storage iron regulation. This huge iron absorption was only possible with oral iron 
supplementation and would not have been possible with mere dietary intake. RHuEPO-
induced iron deficiency was not the driver of increased iron absorption, with ferritin levels 
remaining well within the normal ranges, but we cannot exclude that functional iron 
deficiency could be a mechanism contributing to rHuEPO-enhanced iron absorption since the 
correlation between iron absorption and TSAT was at the limit of significance. It has also 
been demonstrated that hepcidin, which has been shown to inhibit iron absorption and iron 
release by macrophages, is less produced when erythropoiesis is stimulated.28 
In conclusion, rHuEPO therapy was safe and effective, ensuring the success of the AB 
donation program. In addition to its well-known effect on the number of units collected, this 
study also demonstrates the higher quality of units donated under rHuEPO therapy. It 
appeared that mobilizable circulating iron was the best predictor of the number of collectable 
units, reflecting inadequate storage iron release and emphasizing the need for exogenous iron 
supplementation. Oral iron supplementation was proven to be useful as its absorption was 
strongly enhanced by the stimulated erythropoiesis induced by rHuEPO administration.  
Page 12 of 25

































































Yves Beguin is Research Director of the National Fund for Scientific Research (FNRS), 
Belgium. The authors thank Eric Cohen of the Medical College of Wisconsin for his help in 
the correction of this manuscript.
Page 13 of 25

































































1. Goodnough LT. Erythropoietin as a pharmacologic alternative to blood transfusion in the 
surgical patient. Tansfus Med Rev 1990;4:288-296. 
2. Mintz PD. Autologous transfusion endorsed. JAMA 1985;254:507-508. 
3. Toy PTCY, Strauss RG, Stehling, et al. Predeposited autologous blood for elective 
surgery: A national multicenter study. N Engl J Med 1987; 316:517-520. 
4. Goodnough LT, Price TH, Rudnik S. Iron-restricted erythropoiesis as a limitation to 
autologous blood donation in the erythropoietin-stimulated bone marrow. J Lab Clin Med 
1991;118:289-296. 
5. Goodnough LT, Skikne B, Brugnara C. Erythropoietin, iron, and erythropoiesis.  Blood 
2000; 96: 823-833. 
6. Cavill I. Erythropoiesis and iron.  Best Pract Res Clin Haematol 2002; 15: 399-409. 
7. Goodnough LT, Brittenham GM. Limitations of the erythropoietin response to serial 
phlebotomy: Implications for autologous blood donor program. J Lab Clin Med 
1990;115:28-35. 
8. Crosby WH. Treatment of haemochromatosis with energic phlebotomy. One patient’s 
response to letting of 55 litres of blood in 11 months. British Journal of Haematology 
1958;4:82-88. 
9. Sautois B, Baudoux E, Salmon JP et al. Administration of erythropoietin and granulocyte 
colony-stimulating factor in donor/recipient pairs to collect peripheral blood progenitor 
cell (PBPC) and red blood cell units for use in the recipient after allogeneic PBPC 
transplantation. Haematologica 2001;86:1209-1218. 
10. Weisbach V, Skoda P, Rippel R, et al. Oral or intravenous iron as adjuvant to autologous 
blood donation in elective surgery: a randomized, controlled study. Transfusion 
1999;39:465-472.  
Page 14 of 25
































































11. Adamson JW. The erythropoietin/hematocrit relationship in normal and polycythemic 
man: Implications of marrow regulation. Blood 1968;32:597-609. 
12. Barosi G. Inadequate erythropoietin response to anemia: definition and clinical relevance.  
Ann Hematol 1994; 68: 215-223. 
13. Goodnough LT, Bravo J, Hsueh Y et al. Red blood cell volume in autologous and 
allogeneic blood units: Implications for risk/benefit assessment for autologous blood 
“crossover” and directed blood transfusion. Transfusion 1989;29:821-822. 
14. Laupacis A, Fergusson D. Erythropoietin to minimize perioperative blood transfusion: A 
systemic review of randomized trials. The International Study of Peri-operative 
Transfusion (ISPOT) Investigators. Transfus Med 1998;8:309-317. 
15. Goodnough LT, Rudnik S, Price TH, et al. Increased preoperative collection of autologous 
blood with recombinant human erythropoietin therapy. N Engl J Med 1989;321:1163-
1168. 
16. Gordeuk VR, Brittenham GM, Hughes M, et al. High-dose carbonyl iron for iron 
deficiency anemia: a randomized, double-blind trial. Am J Clin Nutr 1987;46:1029-1034. 
17. Holland PV, Schmidt PH, eds. Standards for blood banks and transfusion services. 12th ed. 
Arlington, Va.: American Association of Blood Banks, 1987:39. 
18. Hayashi J, Shinonaga M, Nakazawa S, et al. Does recombinant human erythropoietin 
accelerate erythropoiesis for predonation before cardiac surgery? Jpn Circ J 1993;57:475-
479. 
19. Watanabe M, Kituchi K, Kobayashi K, et al. Autologous blood transfusion for pulmonary 
and mediastinal surgery in 144 patients: The effectiveness of recombinant erythropoietin 
injection. Chest 1994;105:856-859. 
Page 15 of 25
































































20. Goodnough LT, Price TH, Rudnik S. Preoperative red cell production in patients 
undergoing aggressive autologous blood phlebotomy with and without erythropoietin 
therapy. Transfusion 1992;5:441-445. 
21. Biesma DH, Marx JJM, Kraaijenhagen RJ, et al. Lower allogeneic blood requirement in 
autologous blood donors after treatment with recombinant human erythropoietin. Lancet 
1994;344:367-370. 
22. Locatelli F, Aljama P, Barany P, et al. Revised European best practice guidelines for the 
management of anaemia in patients with chronic renal failure.  Nephrol Dial Transplant 
2004; 19 (Suppl 2): ii1-47. 
23. NKF-K/DOQI. IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic 
Kidney Disease: update 2000.  Am J Kidney Dis 2001; 37: S182-S238 
24. Rutherford CJ, Schneider TJ, Dempsey H, et al. Efficacy of different dosing regimens for 
recombinant human erythropoietin in a simulated perisurgical setting: The importance of 
iron availability in optimizing response. Am J Med 1994;96:139-145. 
25. Tasaki T, Ohto H, Nogushi M, et al. Iron and erythropoietin measurement in autologous 
blood donors with anemia: Implication for management. Transfusion 1994;34:337-343. 
26. Goodnough LT, Marcus RE. Erythropoiesis in patients stimulated with erythropoietin: 
The relevance of storage iron. Vox Sang 1998;75:128-133. 
27. Skikne BS, Cook JD. Effect on enhanced erythropoiesis on iron absorption. J Lab Clin 
Med 1992;120:746-751. 
28. Hepcidin: a regulator of intestinal iron absorption and iron recycling by macrophages. 
Best Pract Res Clin Haematol 2005;18:171-182.  
Page 16 of 25

































































Figure 1: RBC volume per unit collected at each donation. The grey area represents the 
normal range for allogeneic blood units.  
*: p<0.05: compared to group 1. 
 
Figure 2: Cumulative RBC production throughout donation visits.  
* : p value < 0.05 when compared to group 1; †: p value < 0.05 when compared to group 2. 
 
Figure 3: Evolution of reticulocyte count (retic), hemoglobin (Hb), EPO serum level (EPO), 
ferritin, soluble trasferrin receptors (sTfR), sTfR/log(ferritin) and transferrin saturation 
(TSAT)during pre-surgery period. Stimulation of erythropoietic activity throughout the study 
as shown by soluble transferin receptor (sTfR) levels.  
 
Figure 4:Correlation between the amount of iron absorbed during the pre-surgery period and 
the peak of reticulocyte count occurring on day 11. 
retic : reticulocyte count. 
 
Figure 5: Relationship between MCI and the number of units donated. The Spearman’s 
correlation coeficient and its p value are given. 
MCI: mobilizable circulating iron.
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Table 1: Baseline parameters
Group 1 
(placebo) 




N 10 11 11 
Age (years) 56 ± 14 63 ± 6 61 ± 13 
Sex (M/F) 3/7 6/5 3/8 
Weight (kg) 69 ± 12 67 ± 9 69 ± 10 
Blood volume (mL) 4,121 ± 730 4,272 ± 523 4,169 ± 617 
RCM (mL) 1,611 ± 344 1,591 ± 254 1,600 ± 290 
Hb (gr/dL) 14.1 ± 1.0 14.1 ± 1.1 13.9 ± 1.1 
Hct (%) 42.3 ± 2.8 43.0 ± 3.0 42.2 ± 3.8 
RBC (106/-L) 4.60 ± 0.38 4.59 ± 0.30 4.48 ± 0.43 
Retic (%) 1.0 ± 0.3 1.7 ± 0.7* 1.1 ± 0.3†
Retic (103/-L) 44.4 ± 13.2 74.8 ± 28.2* 49.0 ± 14.8†
EPO (mU/mL) 12.9 ± 4.4 17.5 ± 8.2 20.1 ± 8.6*
sTfR (ng/mL) 4,140 ± 1270 3,640 ± 300 3,800 ± 1010 
Ferritin (ng/mL) 108 ± 91 178 ± 113 104 ± 59 
SeFe (-mol/mL) 15.9 ± 6.1 17.2 ± 5.6 17.6 ± 6.1 
TIBC (-g/mL) 3.44 ± 0.58 3.04 ± 0.50 3.22 ± 0.44 
TSAT (%) 27 ± 12 32 ± 11 30 ± 10 
Platelets (103/-L) 234 ± 51 248 ± 78 221 ± 61 
Donation period (days) 20 ± 2 20 ± 2 20 ± 1 
SeFe = serum iron; TIBC = total iron binding capacity; TSAT = transferin saturation. 
*: p<0.05, compared to group 1. 
†: p < 0.05, compared to group 2. 
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Table 2: Characteristics of blood donations
Group 1 (placebo) Group 2 (300 UI/kg) Group 3 (600 UI/kg)
Patients donating 1U 0 (0%) 0 (0%) 0 (0%) 
Patients donating 2U 1 (10%) 0 (0%) 0 (0%) 
Patients donating 3U 3 (30%) 1 (9%) 0 (0%) 
Patients donating 4U 5 (50%) 8 (73%) 5 (45%) 
Patients donating 5U 1 (10%) 2 (18%) 6 (55%) 
RBC vol donated/patient (mL) : Day 0 203 ± 34 199 ± 29 200 ± 31 
RBC vol donated/patient (mL) : Day 4 162 ± 61 178 ± 25 185 ± 25 
RBC vol donated/patient (mL) : Day 7 124 ± 89 161 ± 56 150 ± 76 
RBC vol donated/patient (mL) : Day 11 131 ± 70 158 ± 56 168 ± 61 
RBC vol donated/patient (mL) : Day 14 30 ± 63 47 ± 81‡ 147 ± 77* 
RBC vol donated/patient (mL) : total 650 ± 191 743 ± 147 850 ± 159* 
Total RBC vol donated by group (mL) 6,496 8,173 9,354 
BV donated/patient (mL) 1,667 ± 454 1,882 ± 316 2,110 ± 272* 
Hb donated/patient (gr) 212.8 ± 64.3 243.1 ± 52.7 274.2 ± 51.3* 
Total number of units donated by group 36 45 50 
% of target (= 5 x N patients) 72.0 81.8 90.9 
N units/patient 3.60 ± 0.84 4.09 ± 0.54 4.55 ± 0.52†
*: p<0.05; †: p<0.01: compared to group 1 
‡ : p < 0.05 : compared to group 3 
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Table 3: Iron parameters at baseline and at end of donation period
Baseline Pre-surgery
Groups 1 2 3 1 2 3
Ferritin (ng/mL) 108 ± 91 178 ± 113 104 ± 59 50 ± 40 86 ± 63 68 ± 32
SeFe (Wmol/L) 15.9 ± 6.1 17.2 ± 5.6 17.6 ± 6.1 7.7 ± 2.7 9.1 ± 2.3 11.5 ± 8.2
TSAT (%) 27 ± 12 32 ± 11 30 ± 10 14 ± 5 17 ± 4 21 ± 13
MCI (mg) 377 ± 192 390 ± 191 347 ± 185 10 ± 122 79 ± 138 66 ± 161
SI (mg) 745 ± 351 1,010 ± 245 775 ± 339 438 ± 362 714 ± 252 652 ± 190
TMI (mg) 1,122 ± 412 1,400 ± 255 1,122 ± 359 440 ± 413 808 ± 359 718 ± 243
TI (mg) 2,574 ± 569 2,906 ± 334 2,594 ± 497 2,700 ± 662 3,247 ± 559 3,187 ± 538
Donated iron (mg) - - - 724 ± 219 826 ± 179 932 ± 174*
Donated circulating iron (mg) - - - 359 ± 254 579 ± 366 809 ± 351†
Donated storage iron (mg) - - - 363 ± 147 280 ± 247 123 ± 269*
Absorbed iron (mg) - - - 47 ± 198 325 ± 341* 593 ± 286†‡
TSAT = transferrin saturation; SeFe = serum iron
*: p<0.05; †: p<0.01: compared to group 1; ‡: p<0.05: compared to group 2.
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ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901 1 (434) 817-2040 ext. 167
Transfusion
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
